NRX Pharmaceuticals, Inc. (NRXP) shareholders
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| B Group Capital LLC Joint filing with The B Group, Inc. (12.62%), Branden B. Muhl (12.62%) | 3,000,000 | 12.62% | 13G (passive) | Aug 18, 2025 |
| Amin Nathoo Joint filing with Anson Funds Management LP (9.30%), Anson Management GP LLC (9.30%) and 3 more | 1,604,975 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
| Anson Management GP LLC Joint filing with Anson Funds Management LP (7.00%), Tony Moore (7.00%) and 3 more | 1,179,061 | 7.00% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NRXP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| B Group, Inc. | 4,091,767 | 9.45% | $16.74M | +1,091,767 | 7.86% |
| Vanguard Capital Management LLC | 1,618,159 | 3.74% | $6.62M | +457,975 | 0.00% |
| Ameriprise Financial Inc | 928,728 | 2.15% | $3.80M | New | 0.00% |
| Balyasny Asset Management L.P. | 893,864 | 2.06% | $3.66M | New | 0.00% |
| Citadel Advisors LLC | 680,043 | 1.57% | $2.78M | New | 0.00% |
| AdvisorShares Investments LLC | 659,018 | 1.52% | $2.70M | +238,551 | 0.33% |
| Commonwealth Equity Services, LLC | 454,418 | 1.05% | $1.86M | +56,987 | 0.00% |
| UBS Group AG | 423,115 | 0.98% | $1.73M | +397,888 | 0.00% |
| Geode Capital Management, LLC | 314,659 | 0.73% | $1.29M | +4,547 | 0.00% |
| BlackRock, Inc. | 220,460 | 0.51% | $901.68K | +121,465 | 0.00% |
| Marshall Wace, Llp | 194,580 | 0.45% | $795.83K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 182,718 | 0.42% | $747.32K | +13,138 | 0.00% |
| Jane Street Group, LLC | 119,018 | 0.27% | $486.78K | +74,866 | 0.00% |
| Bleakley Financial Group, LLC | 117,216 | 0.27% | $479.41K | +12 | 0.01% |
| State Street Corp | 116,084 | 0.27% | $474.78K | +29,100 | 0.00% |
| Hrt Financial LP | 100,724 | 0.23% | $411.00K | New | 0.00% |
| Northern Trust Corp | 62,951 | 0.15% | $257.47K | +19,482 | 0.00% |
| Chicago Partners Investment Group LLC | 46,388 | 0.11% | $190.66K | +11,909 | 0.00% |
| Quadrature Capital Ltd | 43,605 | 0.10% | $178.34K | New | 0.00% |
| One Wealth Management Investment & Advisory Services, LLC | 43,309 | 0.10% | $177.13K | – | 0.19% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 47 | 12M | 26.9% | 19 / 17 | 4 / 5 | 6M | 0M |
| Q1 2026 | 33 | 6M | 14.3% | 11 / 13 | 1 / 4 | 5M | 3M |
| Q4 2025 | 28 | 5M | 12.1% | 7 / 7 | 10 / 3 | 2M | 1M |
| Q3 2025 | 24 | 4M | 9.1% | 4 / 13 | 3 / 5 | 1M | 0M |
| Q2 2025 | 25 | 3M | 6.9% | 5 / 10 | 4 / 2 | 1M | 0M |
| Q1 2025 | 22 | 2M | 5.2% | 4 / 6 | 5 / 7 | 1M | 0M |
| Q4 2024 | 25 | 1M | 2.4% | 10 / 4 | 3 / 3 | 0M | 0M |
| Q3 2024 | 18 | 1M | 1.6% | 4 / 4 | 3 / 4 | 0M | 0M |
| Q2 2024 | 19 | 1M | 1.2% | 19 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held NRXP in Q2 2026, 89% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NRXP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,267,102 | 2.93% | $5.18M | 0.00% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 659,018 | 1.52% | $2.70M | 6.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 291,393 | 0.67% | $1.19M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 131,299 | 0.30% | $580.34K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 104,969 | 0.24% | $429.32K | 0.03% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 48,123 | 0.11% | $212.70K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 30,812 | 0.07% | $136.19K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 21,976 | 0.05% | $97.13K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 21,717 | 0.05% | $88.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 15,459 | 0.04% | $63.23K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 7,113 | 0.02% | $29.09K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 4,275 | 0.01% | $13.47K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 634 | 0.00% | $2.59K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,211 | -0.00% | -$4.95K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan C. Javitt | CEO and Chairman, Director | 1,516,834 | 3.50% | Nov 4, 2026 |
| Michael S. Abrams | Chief Financial Officer | – | – | Nov 4, 2026 |
| Joseph Michael Casper | Chief Operating Officer | – | – | Feb 17, 2026 |
| Patrick John Flynn | Director | 39,459 | 0.09% | Sep 10, 2025 |
| Chaim Hurvitz | Director | 2,214,793 | 5.12% | Sep 10, 2025 |
| Dennis McBride | Director | – | – | Sep 10, 2025 |
| B Group, Inc. | 10% owner | 3,000,000 | 6.93% | Aug 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan C. Javitt Chairman and Chief Scientist, Director, 10% owner | Dec 17, 2024 | Buy | +40,000 | $1.17 | $46.80K | 84,634 |
| Aaron Gorovitz Director | Aug 30, 2023 | Buy | +35,000 | $0.32 | $11.20K | 105,000 |
| Chaim Hurvitz Director | Aug 30, 2023 | Buy | +70,000 | $0.29 | $20.30K | 570,000 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Aug 23, 2023 | Buy | +100,000 | $0.33 | $33.00K | 446,332 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Aug 22, 2023 | Buy | +200,000 | $0.32 | $64.00K | 346,332 |
| Stephen H. Willard CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2022 | Buy | +50,000 | $1.17 | $58.50K | 50,000 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Dec 16, 2022 | Buy | +30,000 | $1.10 | $33.00K | 46,337 |
| Jonathan C. Javitt Director, 10% owner | Dec 14, 2022 | Gift | −300,000 | – | – | 14,468,329 |
| Jonathan C. Javitt Director, 10% owner | Dec 7, 2022 | Sale | −400,000 | $1.00 | $400.00K | 12,899,997 |
| Daniel C. Javitt 10% owner | Nov 30, 2022 | Sale(10b5-1 plan) | −8,441 | $1.50 | $12.66K | 9,634,793 |
| Daniel C. Javitt 10% owner | Nov 29, 2022 | Sale(10b5-1 plan) | −13,730 | $1.50 | $20.60K | 9,643,234 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 37,709 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 37,709 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.24 | $3.10K | 40,209 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +1,750 | $1.25 | $2.19K | 1,750 |
| Patrick John Flynn Director | Nov 28, 2022 | Buy | +2,500 | $1.25 | $3.13K | 40,209 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +7,021 | $1.11 | $7.79K | 16,337 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +8,716 | $1.12 | $9.76K | 8,716 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +600 | $1.10 | $660 | 9,316 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +8,716 | $1.12 | $9.76K | 8,716 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +600 | $1.10 | $660 | 9,316 |
| Voorhees Seth Van CHIEF FINANCIAL OFFICER | Nov 25, 2022 | Buy | +7,021 | $1.11 | $7.79K | 16,377 |
| Chaim Hurvitz Director | Nov 18, 2022 | Buy | +40,408 | $1.10 | $44.45K | 500,000 |
| Chaim Hurvitz Director | Nov 18, 2022 | Buy | +40,408 | $1.10 | $44.45K | 500,000 |
| Chaim Hurvitz Director | Nov 17, 2022 | Buy | +171,780 | $1.08 | $185.52K | 459,592 |
| Chaim Hurvitz Director | Nov 17, 2022 | Buy | +171,780 | $1.08 | $185.52K | 459,592 |
| Daniel C. Javitt 10% owner | Nov 17, 2022 | Sale(10b5-1 plan) | −33,018 | $1.05 | $34.67K | 9,656,964 |
| Chaim Hurvitz Director | Nov 16, 2022 | Buy | +287,812 | $0.99 | $284.93K | 287,812 |
| Chaim Hurvitz Director | Nov 16, 2022 | Buy | +287,812 | $0.99 | $284.93K | 287,812 |
| Daniel C. Javitt 10% owner | Nov 16, 2022 | Sale(10b5-1 plan) | −133,719 | $1.02 | $136.39K | 9,689,982 |
| Daniel C. Javitt 10% owner | Nov 11, 2022 | Sale(10b5-1 plan) | −49,200 | $1.01 | $49.69K | 9,823,701 |
| Daniel C. Javitt 10% owner | Jul 29, 2022 | Sale | −784,063 | $1.01 | $791.90K | 9,872,901 |
| Daniel C. Javitt 10% owner | Jul 1, 2022 | Gift | −2,000,000 | – | – | 10,656,964 |
| Daniel C. Javitt 10% owner | Jun 7, 2022 | Sale | −86,459 | $0.65 | $56.20K | 12,656,964 |
| Daniel C. Javitt 10% owner | Jun 6, 2022 | Sale | −115,657 | $0.67 | $77.49K | 12,743,423 |
| Daniel C. Javitt 10% owner | Jun 3, 2022 | Sale | −243,596 | $0.70 | $170.52K | 12,859,080 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Jun 1, 2022 | Buy | +100,000 | $0.58 | $58.00K | 146,332 |
| Jonathan C. Javitt Chief Scientist, Director, 10% owner | Jun 1, 2022 | Buy | +100,000 | $58.00 | $5.80M | 146,332 |
| Robert Besthof Chief Comm. & Patient Officer | Sep 15, 2021 | Sale | −40,000 | $11.76 | $470.40K | 23,710 |
| Alessandra Daigneault General Counsel & Secretary | Sep 2, 2021 | Option exercise | +18,420 | $3.07 | $56.55K | 18,420 |
| Alessandra Daigneault General Counsel & Secretary | Sep 2, 2021 | Option exercise | +13,164 | $3.07 | $40.41K | 31,584 |
| Herbert Raymond McMaster Director | Aug 26, 2021 | Option exercise | +18,300 | $2.22 | $40.63K | 18,300 |
| Alessandra Daigneault General Counsel & Secretary | Aug 23, 2021 | Sale | −33,715 | $13.11 | $442.00K | 0 |
| Alessandra Daigneault General Counsel & Secretary | Aug 19, 2021 | Option exercise | +27,395 | $3.07 | $84.10K | 33,715 |
| Robert Besthof Chief Comm. & Patient Officer | Aug 16, 2021 | Option exercise | +63,710 | $0.20 | $12.74K | 63,710 |
| Daniel C. Javitt 10% owner | Jul 16, 2021 | Gift | −434,594 | – | – | 13,102,676 |
| Daniel C. Javitt 10% owner | Jul 16, 2021 | Gift | −434,594 | – | – | 13,537,270 |
| Patrick John Flynn Director | May 24, 2021 | Award | +362,332 | – | – | 362,332 |
| Patrick John Flynn Director | May 24, 2021 | Award | +35,209 | – | – | 35,209 |
| Patrick John Flynn Director | May 24, 2021 | Award | +35,209 | – | – | 35,209 |
| Chaim Hurvitz Director | May 24, 2021 | Award | +208,443 | – | – | 208,443 |
| Chaim Hurvitz Director | May 24, 2021 | Award | +1,436,350 | – | – | 1,436,350 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +8,336 | – | – | 8,336 |
| Aaron Gorovitz Director | May 24, 2021 | Award | +16,678 | – | – | 16,678 |
| Sharon Glied Director | May 24, 2021 | Award | +13,168 | – | – | 13,168 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +46,332 | – | – | 46,332 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +1,422,000 | – | – | 1,422,000 |
| Jonathan C. Javitt Chief Executive Officer, Director, 10% owner | May 24, 2021 | Award | +13,348,997 | – | – | 13,348,997 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NRX Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 97,603 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?